세계의 속효성 인슐린 시장 보고서(2025년)

Short-acting insulin is a type of insulin used to manage blood sugar levels during or after meals. It begins acting within 30 minutes to 1 hour, peaks around 2-3 hours, and lasts for approximately 4-6 hours. This insulin type plays a crucial role in glucose regulation by promoting glucose uptake into cells for energy, particularly after food consumption.

The main formulations of short-acting insulin include regular insulin and rapid-acting insulin. Regular insulin is a fast-acting insulin variant used to control blood sugar levels, typically administered before meals. These formulations are available in various dosage forms, including vials, pre-filled pens, and cartridges, and can be administered via subcutaneous or intravenous routes. Short-acting insulin is prescribed for both type 1 and type 2 diabetes patients and is distributed through retail pharmacies, hospital pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The short-acting insulin market research report is one of a series of new reports from The Business Research Company that provides short-acting insulin market statistics, including the short-acting insulin industry global market size, regional shares, competitors with the short-acting insulin market share, detailed short-acting insulin market segments, market trends, and opportunities, and any further data you may need to thrive in the short-acting insulin industry. This short-acting insulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The short-acting insulin market size has grown steadily in recent years. It will grow from $11 billion in 2024 to $11.54 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to an increase in the type 1 diabetes population, a rising geriatric population, a surge in research and development funding, the prevalence of diagnosed instances, and increasing urbanization.

The short-acting insulin market size is expected to see strong growth in the next few years. It will grow to $14.14 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to an increase in initiatives taken by the government, an increase in government support, rapid innovations in production, increasing adoption of insulin therapy, and the rise of personalized medicine. Major trends in the forecast period include advancements in insulin delivery devices and technologies, innovative fast-acting insulin analogs, the development of biosimilars, a shift towards patient-centric care, and advancements in formulation.

The forecast of 5.2% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder diabetic care by inflating prices of rapid-acting insulin analogs sourced from Denmark and Puerto Rico, potentially compromising glucose control and increasing endocrinology treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of type 1 diabetes is expected to drive the growth of the short-acting insulin market. Type 1 diabetes is an autoimmune condition in which the body destroys insulin-producing cells, necessitating lifelong insulin therapy. The increasing incidence of type 1 diabetes is influenced by genetic factors, environmental triggers, and a rise in autoimmune disorders. Short-acting insulin plays a crucial role in managing the condition by providing rapid blood sugar control and mimicking the body's natural insulin response. For example, in 2023, Diabetes Australia, an organization dedicated to raising awareness about diabetes, reported that approximately 134,000 Australians were living with type 1 diabetes in 2022, a number that increased to 135,423 in 2023. As a result, the growing prevalence of type 1 diabetes is fueling the expansion of the short-acting insulin market.

Leading companies in the short-acting insulin market are developing innovative products such as insulin pods to enhance insulin delivery and improve adherence for diabetes patients. An insulin pod is a tubeless, wearable insulin delivery system that provides continuous insulin infusion for diabetes management. In April 2023, Insulet Corporation, a US-based medical device company, received FDA clearance for Omnipod GO, a pioneering basal-only insulin pod designed for adults with type 2 diabetes. This tubeless, wearable device delivers continuous insulin without requiring a separate controller. By eliminating the need for daily injections and offering pre-programmed insulin rates, Omnipod GO simplifies diabetes management. Its user-friendly design and pharmacy accessibility enhance convenience for both patients and healthcare providers, reinforcing Insulet's commitment to advancing diabetes care through innovative technology.

In December 2024, Lupin Limited, an India-based pharmaceutical company, acquired the Humulin range in India from Eli Lilly & Company for an undisclosed amount. This acquisition strengthens Lupin's position in the Indian insulin market by expanding its product portfolio with the addition of Huminsulin from Eli Lilly & Company. Eli Lilly & Company, a US-based pharmaceutical firm, specializes in insulin products, including short-acting insulin, further reinforcing Lupin's commitment to providing comprehensive diabetes care solutions.

Major players in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Baxter International Inc., Eisai Co. Ltd., Sumitomo Pharma Co. Ltd., Biocon Limited, Kissei Pharmaceutical Co. Ltd., Lupin Limited, Wockhardt Ltd., Lannett Co. Inc., MannKind Corporation, Sihuan Pharmaceutical Holdings Group Ltd., Julphar(Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., hec pharm co. ltd, ADOCIA SAS, Gan & Lee Pharmaceuticals Co. Ltd., and Adocia S.A.S.

North America was the largest region in the short-acting insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in short-acting insulin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the short-acting insulin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The short-acting insulin market consists of sales of human insulin, analogue insulin, and biosimilars. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Short-Acting Insulin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on short-acting insulin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for short-acting insulin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The short-acting insulin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Formulation: Regular Insulin; Rapid-Acting Insulin
• 2) By Dosage Form: Vials; Pre-filled Pens; Cartridges
• 3) By Route Of Administration: Subcutaneous; Intravenous
• 4) By Patient Type: Type 1 Diabetes; Type 2 Diabetes
• 5) By Distribution Channel: Pharmacies; Hospital Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Regular Insulin: Human Regular Insulin; Animal-Derived Regular Insulin; Other Regular Insulin
• 2) By Rapid-Acting Insulin: Insulin Lispro; Insulin Aspart; Insulin Glulisine
• Companies Mentioned: Sanofi S.A.; Eli Lilly and Company; Novo Nordisk A/S; Baxter International Inc.; Eisai Co. Ltd.; Sumitomo Pharma Co. Ltd.; Biocon Limited; Kissei Pharmaceutical Co. Ltd.; Lupin Limited; Wockhardt Ltd.; Lannett Co. Inc.; MannKind Corporation; Sihuan Pharmaceutical Holdings Group Ltd.; Julphar(Gulf Pharmaceutical Industries); Geropharm LLC; Bioton S.A.; hec pharm co. ltd; ADOCIA SAS; Gan & Lee Pharmaceuticals Co. Ltd.; Adocia S.A.S.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Short-Acting Insulin Market Characteristics

3. Short-Acting Insulin Market Trends And Strategies

4. Short-Acting Insulin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Short-Acting Insulin Growth Analysis And Strategic Analysis Framework

• 5.1. Global Short-Acting Insulin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Short-Acting Insulin Market Growth Rate Analysis
• 5.4. Global Short-Acting Insulin Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Short-Acting Insulin Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Short-Acting Insulin Total Addressable Market (TAM)

6. Short-Acting Insulin Market Segmentation

• 6.1. Global Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Regular Insulin
• Rapid-Acting Insulin
• 6.2. Global Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vials
• Pre-filled Pens
• Cartridges
• 6.3. Global Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subcutaneous
• Intravenous
• 6.4. Global Short-Acting Insulin Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1 Diabetes
• Type 2 Diabetes
• 6.5. Global Short-Acting Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• 6.6. Global Short-Acting Insulin Market, Sub-Segmentation Of Regular Insulin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Human Regular Insulin
• Animal-Derived Regular Insulin
• Other Regular Insulin
• 6.7. Global Short-Acting Insulin Market, Sub-Segmentation Of Rapid-Acting Insulin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin Lispro
• Insulin Aspart
• Insulin Glulisine

7. Short-Acting Insulin Market Regional And Country Analysis

• 7.1. Global Short-Acting Insulin Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Short-Acting Insulin Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Short-Acting Insulin Market

• 8.1. Asia-Pacific Short-Acting Insulin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Short-Acting Insulin Market

• 9.1. China Short-Acting Insulin Market Overview
• 9.2. China Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Short-Acting Insulin Market

• 10.1. India Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Short-Acting Insulin Market

• 11.1. Japan Short-Acting Insulin Market Overview
• 11.2. Japan Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Short-Acting Insulin Market

• 12.1. Australia Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Short-Acting Insulin Market

• 13.1. Indonesia Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Short-Acting Insulin Market

• 14.1. South Korea Short-Acting Insulin Market Overview
• 14.2. South Korea Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Short-Acting Insulin Market

• 15.1. Western Europe Short-Acting Insulin Market Overview
• 15.2. Western Europe Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Short-Acting Insulin Market

• 16.1. UK Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Short-Acting Insulin Market

• 17.1. Germany Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Short-Acting Insulin Market

• 18.1. France Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Short-Acting Insulin Market

• 19.1. Italy Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Short-Acting Insulin Market

• 20.1. Spain Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Short-Acting Insulin Market

• 21.1. Eastern Europe Short-Acting Insulin Market Overview
• 21.2. Eastern Europe Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Short-Acting Insulin Market

• 22.1. Russia Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Short-Acting Insulin Market

• 23.1. North America Short-Acting Insulin Market Overview
• 23.2. North America Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Short-Acting Insulin Market

• 24.1. USA Short-Acting Insulin Market Overview
• 24.2. USA Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Short-Acting Insulin Market

• 25.1. Canada Short-Acting Insulin Market Overview
• 25.2. Canada Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Short-Acting Insulin Market

• 26.1. South America Short-Acting Insulin Market Overview
• 26.2. South America Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Short-Acting Insulin Market

• 27.1. Brazil Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Short-Acting Insulin Market

• 28.1. Middle East Short-Acting Insulin Market Overview
• 28.2. Middle East Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Short-Acting Insulin Market

• 29.1. Africa Short-Acting Insulin Market Overview
• 29.2. Africa Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Short-Acting Insulin Market Competitive Landscape And Company Profiles

• 30.1. Short-Acting Insulin Market Competitive Landscape
• 30.2. Short-Acting Insulin Market Company Profiles
  • 30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Eisai Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Short-Acting Insulin Market Other Major And Innovative Companies

• 31.1. Sumitomo Pharma Co. Ltd.
• 31.2. Biocon Limited
• 31.3. Kissei Pharmaceutical Co. Ltd.
• 31.4. Lupin Limited
• 31.5. Wockhardt Ltd.
• 31.6. Lannett Co. Inc.
• 31.7. MannKind Corporation
• 31.8. Sihuan Pharmaceutical Holdings Group Ltd.
• 31.9. Julphar(Gulf Pharmaceutical Industries)
• 31.10. Geropharm LLC
• 31.11. Bioton S.A.
• 31.12. hec pharm co. ltd
• 31.13. ADOCIA SAS
• 31.14. Gan & Lee Pharmaceuticals Co. Ltd.
• 31.15. Adocia S.A.S.

32. Global Short-Acting Insulin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Short-Acting Insulin Market

34. Recent Developments In The Short-Acting Insulin Market

35. Short-Acting Insulin Market High Potential Countries, Segments and Strategies

• 35.1 Short-Acting Insulin Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Short-Acting Insulin Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Short-Acting Insulin Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer